

Atty Docket No. 15280W-003000

PTO FAX NO.: 703-308-4556

ATTENTION: Examiner Barbara P. Badio  
Group Art Unit 1616

FAX RECEIVED

APR 23 2003

GROUP 1600

**OFFICIAL COMMUNICATION**  
**FOR THE PERSONAL ATTENTION OF**  
**EXAMINER BADIO**

OFFICIAL

**CERTIFICATION OF FACSIMILE TRANSMISSION**


I hereby certify that the following documents, in re Application of Hyun K. Kim et al., Application No. 09/526,855, filed March 17, 2000, is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Documents Attached

1. Amendment Under 37 CFR 1.116.

Number of pages being transmitted, including this page: 19

Dated: April 22, 2003

  
Linda Shaffer

**PLEASE CONFIRM RECEIPT OF THIS PAPER BY**  
**RETURN FACSIMILE AT (415) 576-0300**

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, CA 94111-3834  
Telephone: (415) 576-0200  
Fax: (415) 576-0300

WC 9058805 v1

I hereby certify that this correspondence is being facsimile  
transmitted to the United States Patent and Trademark Office,  
Fax No. 703-308-4556 on 4-22-03.

AMENDMENT UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE -  
EXAMINING GROUP 1616

#24C  
m. m.  
4/24/03  
n.e.

TOWNSEND and TOWNSEND and CREW LLP

By: Linda Shaffer

PATENT  
Attorney Docket No.: 15280W-003000  
Client Ref. No.: E-155-99/0

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Hyun K. Kim, *et al.*

Application No.: 09/526,855

Filed: March 17, 2000

For: STRUCTURAL MODIFICATION  
OF 19-NORPROGESTERONE 17-  
ALPHA-SUBSTITUTED-11-BETA-  
SUBSTITUTED-4-ARYL AND 21-  
SUBSTITUTED 19-  
NORPREGNADIENEDIONE AS NEW  
ANTI-PROGESTATIONAL AGENTS

Examiner: Barbara P. Badio

AMENDMENT UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE EXAMINING  
GROUP 1616

**Mail Stop AF**

Commissioner for Patents, Box 1450  
Alexandria, VA 22313-1450

Sir:

This Amendment is submitted in response to the Final Office Action mailed  
February 26, 2003.

This amendment has been prepared under the newly revised format set forth by  
the USPTO in the Office of Patent Legal Administration Pre-OG Notice of January 31, 2003. It  
is Applicants understanding that by following the provisions of the new format, the provisions  
under 37 CFR § 1.121(a), (b), (c) and (d) are waived for amendments to the claims, specification  
and drawings.